What Is US Drug Patent 7,458,374 Covering and How Broad Are the Claims?
US Patent 7,458,374 claims a rapid-heating device and methods for vaporizing a drug formulation that is coated on a metallic surface using a combustible element inside a sealed fuel cell with an igniter exposed to the combustible element. The disclosed device is structured to produce drug vapor for inhalation via a housing and mouthpiece, with embodiments that separate ignition power from the fuel-cell section via a detachable housing interface.
The claim set is organized around two device architectures and two corresponding vaporization methods:
- Device A (Claim 1 family): drug is coated on a metallic substrate (interior surface around a surface), which is heated by a combustible element contained inside a sealed fuel cell with an igniter exposed to the combustible.
- Device B (Claim 9 family): drug is coated on the exterior surface of the fuel cell, heated directly by ignition of the combustible element inside the sealed fuel cell.
Both architectures include inhalation hardware (housing, mouthpiece) and optional power source/detachable sections (Claim 15 and Claim 29).
Claim-by-Claim Scope: What Exactly Is Required?
What do independent claims 1 and 9 require?
Claim 1 (Device for rapid heating of a coated composition)
To infringe claim 1, an accused device must include all of the following elements in combination:
- A device for rapid heating of a coated composition
- A metallic substrate that has an interior surface surrounding a surface
- A combustible element contained within a sealed fuel cell, configured to provide heat upon ignition
- An igniter exposed to the combustible element for igniting it
- A composition comprising at least one drug coated on the surface of the metallic substrate
In short: drug-coated metal substrate + combustion-in-fuel-cell heat source + exposed igniter.
Claim 9 (Device for rapid heating where drug is coated on the fuel cell exterior)
Claim 9 requires:
- A device for rapid heating of a coated composition
- A combustible element inside a sealed fuel cell with an exterior surface
- The combustible element provides heat upon ignition
- An igniter exposed to ignite the combustible element
- A composition comprising at least one drug coated on the exterior surface of the fuel cell
In short: drug-coated fuel-cell exterior + combustion-in-fuel-cell heat source + exposed igniter.
What do dependent claims narrow?
The dependent claims primarily narrow materials, structural integration, inhalation integration, and ignition/power separation.
Material and structure narrowing
- Claim 2 / Claim 10: metallic substrate (or fuel cell) is stainless steel or aluminum
- Claim 3: metallic substrate comprises a sheath around the fuel cell
- Claim 4: combustible element comprises a combustible metal
- Claim 5 / Claim 12: combustible metal is one of magnesium, zirconium, aluminum
- Claim 6: metallic substrate is coated onto the fuel cell
- Claim 11 / Claim 12: fuel-cell architecture tied to combustible metal species list
These are meaningful because they create explicit “at least one of” lists that can be mapped to common metal choices used in ignition/fuel-cell heater designs.
Inhalation integration narrowing
- Claim 7 / Claim 13: housing containing the heated element to facilitate inhalation of the drug after vaporization
- Claim 8 / Claim 14: housing includes a mouthpiece
These claims do not require specific airflow mechanics, valves, or aerosol particle size targets. They require the presence of a housing and a mouthpiece for oral inhalation.
Power source and detachable sections
- Claim 15: adds a power source for ignition, and requires a two-section housing:
- first section contains power source
- second section contains metallic substrate and combustible element
- first section detachable from second section
- Claim 29: analogous structure:
- first section contains power source
- second section contains metallic substrate and combustible element
- first section detachable from second section
This is a clear mechanical interface claim around a removable heater/fuel-cell cartridge and a separate battery/ignition module.
Drug composition category
- Claims 21, 22, 23, 24, 25, 26, 27, 28: drug composition is either:
- a pure active compound, and/or
- includes a pharmaceutically acceptable excipient
Notably, these are composition-type dependent features that can broaden coverage if an accused product includes excipients or uses a pure active. The base independent claims already require “at least one drug coated,” so these dependents capture typical formulation states.
What do independent methods require?
Claim 16 (Method corresponding to Claim 1 device architecture)
Method requires:
- Provide a metallic substrate with a surface
- Coat a composition with at least one drug on the metallic substrate surface
- Provide a combustible element contained inside a sealed fuel cell
- Ignite combustible element to heat the drug-coated metallic substrate
- Produce a vapor comprising the drug
Claim 20 (Method corresponding to Claim 9 device architecture)
Method requires:
- Provide a combustible element contained within a sealed fuel cell with an exterior surface
- Coat the exterior surface with a composition having at least one drug
- Ignite combustible element to heat the drug-coated exterior surface
- Produce drug vapor
What do dependent method claims add?
- Claim 17 / Claim 31: stainless steel or aluminum substrate/fuel cell
- Claim 18 / Claim 32: combustible metal is magnesium/zirconium/aluminum
- Claim 19 / Claim 33: substrate/fuel cell contained within a housing facilitating aerosolization
- Claim 30 / Claim 34: aerosolize vapor and administer by inhalation
These method dependents add a downstream clinical-administration pathway, but do not require an inhalation device beyond the general “administer by inhalation” language.
How Much Coverage Is There: Element Mapping and Infringement Levers
Key claim “hooks”
Across the independent claims (devices) and independent methods, the scope concentrates on five technical hooks:
- Drug is coated on a metallic surface (substrate or fuel-cell exterior)
- Heating is driven by combustion in a sealed fuel cell
- The heater includes an igniter exposed to combustible element
- Metals are selectable in certain dependents:
- Stainless steel or aluminum
- Magnesium, zirconium, aluminum combustible metal
- The device is integrated with an inhalation housing and mouthpiece
- Optional but strong structural boundary: detachable power section vs separate fuel-cell/heater section
Design-around options (what to avoid to reduce literal risk)
Based strictly on claim language, a manufacturer has several potential levers:
- Do not coat the drug on the surface of a metallic substrate (Claim 1 family) or the exterior surface of the fuel cell (Claim 9 family). For example, drug could be on a non-metal substrate, or in a form that is not “coated” onto the specified surfaces.
- Avoid having a combustible element in a sealed fuel cell in the claimed sense.
- Avoid an igniter exposed to the combustible element (structural separation between igniter and combustible may matter).
- Avoid the specific metal selections if relying on dependents (stainless steel/aluminum; magnesium/zirconium/aluminum). But note: independent claims 1 and 9 do not require these lists, so metal choices only affect dependent claim infringement.
- Do not include an inhalation housing with a mouthpiece if you only need to escape dependent claim 8/14 or method 30/34. Independent claims 1/9 can still read without them, because inhalation components are not in those independents.
- The detachable power boundary (Claim 15/29) is a risk point for products with separate battery ignition module and removable cartridge.
Patent Landscape: Where US 7,458,374 Likely Sits Relative to Similar Tech
What this patent is within the broader market
US 7,458,374 is a classic “heater device for drug vapor” patent with:
- combustion-based heat generation,
- sealed fuel-cell heater geometry,
- and formulation-on-metal coating.
That positions it in a competitive area that overlaps with:
- inhalable vapor generation devices for pharmaceuticals,
- combustion or exothermic heater platforms for rapid onset delivery,
- and cartridge-style removable heater architectures with separate power.
Landscape structure you should use in diligence
For portfolio strategy, map competitors and freedom-to-operate (FTO) along three layers:
-
Device heater architecture
- sealed fuel cell
- exposed igniter geometry
- combustible element selection and placement
-
Formulation placement
- coated on metal substrate vs coated on fuel cell exterior
- coated composition includes excipients vs pure active compound
-
Delivery assembly
- housing + mouthpiece
- aerosolization and inhalation steps
US 7,458,374 provides claim coverage at layers 1 and 2 in the independents, and at layer 3 in dependents (device 7/8 and 13/14; methods 30 and 34), while also capturing cartridge/battery modularity (Claim 15 and 29).
Scope Summary Table: Independent vs Dependent “Required Elements”
| Claim |
Architecture |
Drug placement required |
Heat source requirement |
Ignition requirement |
Inhalation requirement (explicit) |
| 1 |
metallic substrate around/with interior surface |
drug coated on metallic substrate surface |
combustible element inside sealed fuel cell |
igniter exposed to combustible |
Not required |
| 9 |
fuel-cell exterior heating surface |
drug coated on fuel cell exterior surface |
combustible element inside sealed fuel cell |
igniter exposed to combustible |
Not required |
| 16 |
method aligned to Claim 1 |
coat drug on metallic substrate |
ignite combustible inside sealed fuel cell |
ignition produces heating and vapor |
Not required |
| 20 |
method aligned to Claim 9 |
coat drug on fuel cell exterior |
ignite combustible inside sealed fuel cell |
ignition produces heating and vapor |
Not required |
| 15 / 29 |
device modularity |
depends on 1 or 9 architecture |
combustible in sealed fuel cell |
power source for ignition |
housing is implied structurally |
| 7/8/13/14 |
inhalation assembly |
depends on 1 or 9 architecture |
same |
same |
housing and mouthpiece required |
Practical Claim-Strategic Read: What Would Be “Most Litigable”?
The most litigation-prone aspects are those that are both (a) central to independents and (b) easy for competitors to accidentally copy:
- combustible element inside a sealed fuel cell
- igniter exposed to combustible element
- drug coating on metal surfaces (either substrate or fuel-cell exterior)
Secondary litigation points:
- detachable power section design (Claim 15/29)
- mouthpiece housing integration (Claim 8/14 and method aerosolization/admin by inhalation)
Material-selection dependents (stainless steel/aluminum; magnesium/zirconium/aluminum) likely matter in later-stage refinement but do not fully control independent claim coverage.
Key Takeaways
- US 7,458,374 covers combustion-in-sealed-fuel-cell heating of a drug-coated metal surface for drug vapor production aimed at inhalation systems.
- Coverage is split into two core claim architectures: drug coated on a metallic substrate (Claim 1 / 16) and drug coated on the fuel-cell exterior (Claim 9 / 20).
- Igniter exposure to the combustible element and the sealed fuel cell structure are central, high-impact claim elements.
- Inhalation hardware (housing, mouthpiece) and aerosolization/admin by inhalation are included in dependents, while detachable power/battery vs heater section is captured in modularity dependents (Claim 15/29).
- Metal lists (stainless steel/aluminum; Mg/Zr/Al combustible) constrain only some dependents, so design around must primarily address architecture and drug-coating placement, not only materials.
FAQs
-
Does US 7,458,374 require the drug to be on a metal substrate?
Yes, at least one independent claim requires the drug composition to be coated on either a metallic substrate surface (Claim 1/16) or the exterior surface of the fuel cell (Claim 9/20).
-
Is a mouthpiece required for infringement of the broadest device claims?
No. A mouthpiece appears in dependents (Claim 8/14). Independents 1 and 9 do not require it.
-
What is the core heater technology in the claims?
A combustible element housed in a sealed fuel cell, heated by ignition via an igniter exposed to the combustible element.
-
Can the drug formulation be a pure active compound and still fall within the claims?
Yes. The claim set includes dependent claims where the drug composition is a pure active compound and/or includes pharmaceutically acceptable excipient.
-
Does the patent cover detachable battery/cartridge-style designs?
Yes. Claim 15 and Claim 29 add a detachable first section containing the power source from a second section containing the fuel-cell/heater components.
References
[1] U.S. Patent No. 7,458,374.
